1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

---

Medicinova, a biopharmaceutical company, announced FDA approved orphan drug designation for its leading medical treatment, MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). Currently, there is only one approved...

Read More

---

EU Union grants orphan drug status to GLPG1690 for idiopathic pulmonary fibrosis

Release Date: 13 November 2016

Galapagos, a bio-technology company dedicated to produce small molecule medicines with novel modes of action, declared that its novel medication GLPG1690 has been approved as orphan drug by European Commission for the treatment of idiopa...

Read More

---

Firdapse gets orphan drug status for treatment of Myasthenia Gravis

Release Date: 12 November 2016

Catalyst pharmaceuticals Inc., a biopharmaceutical company, declare its novel therapy Firdapse (amifampridine phosphate) as orphan drug for the treatment of patients with Myasthenia Gravis, as approved by Food and Drug Association (FDA)....

Read More

---

FDA announces orphan drug designation for TG-1101 for NMO and NMOSD

Release Date: 11 November 2016

TG Therapeutics Inc., a biopharmaceutical company  focusing on developing and commercializing the medicines or treatments for B-cell malignancies and auto-immune diseases, developed TG-1101 (ublituximab), the company’s novel p...

Read More

---

TiGenix’s Cx601 granted as orphan drug designation in Switzerland

Release Date: 10 November 2016

TiGenix NV, a biopharmaceutical company, focused on developing novel therapeutics from its proprietary platform of allogeneic expanded stem cells, declared that its leading product Cx601, has been granted orphan drug designation status i...

Read More

---

EMA announces orphan drug designation for ABO-102 gene therapy

Release Date: 09 November 2016

Abeona Therapeutics Inc., a biopharmaceutical company dedicated to develop gene therapies for life threatening rare diseases declared that leading therapy ABO-102 has been designated as orphan drug b European Medicines Agency (EMA) for t...

Read More

---

EMA declares orphan drug designation to Masitinib for Lou Gehrig's disease

Release Date: 23 October 2016

AB Science SA, a pharmaceutical company specialized in research, development and commercialization of protein kinase inhibitors (PKIs), announces that European Medicines Agency has granted Masitinib, orphan drug designation  for the...

Read More

---

Regenicin's NovaDerm designated as Orphan drug for skin grafting: FDA

Release Date: 22 October 2016

Food and Drug Association (FDA) has granted orphan drug designation for Novaderm, discovered by Regenicin Inc., a pharmaceutical company engaged in development and regeneration of cell therapies to restore health of damaged tissues and o...

Read More

---

FDA grants VX15 from Vaccinex Inc. Orphan Drug designation for Huntington’s disease

Release Date: 21 October 2016

VX15 developed by Vaccinex Inc., a pharmaceutical company focusing on the discovery and development of therapeutic monoclonal antibodies to treat patients with cancer and neurodegenerative diseases, has been designated as orphan drug by ...

Read More

---

Tivorsan receives orphan drug designation for Human Recombinant Biglycan for DMD

Release Date: 20 October 2016

Tivorsan pharmaceutical, a company focusing on developing drugs and treatments for all kinds of Duchenne Muscular Dystrophy (DMD) and other neuromuscular disorders, declared that food and Drug Association (FDA) has granted Orphan drug de...

Read More

---

FDA grants Biotie’s BTT1023 orphan drug designation

Release Date: 19 October 2016

Food and Zdrug Association (FDA) grants orphan drug designation to BTT1023, developed by Biotie, a company focusing on neurodegenerative and psychiatric diseases for treatment of primary sclerosing cholangitis (PSC), a progressive f...

Read More

---

First orphan drug introduced for Friedreich’s Ataxia: FDA

Release Date: 18 October 2016

Agilis Biotherapeutics, LLC (Read More

---

European commission declares orphan drug status for Alexion’s ALXN1007

Release Date: 18 October 2016

Alexion Pharmaceuticals Inc., announced that European commission has designated ALXN1007 as orphan drug for treatment of patients with graft-versus-host diseases (GVHD). The company is, presently, working on ALXN1007’s efficacies i...

Read More

---

FDA grants TGR1202 orphan drug designation for Chronic Lymphocytic Leukemia

Release Date: 17 October 2016

T.G therapeutics, a bio pharmaceutical company based on developing drugs and effective treatments for B-cell malignancies and autoimmune diseases, declares it’s oral, next generation PI3K Delta inhibitor, TGR 1202,  as an orph...

Read More

---

Ovarian Cancer gets Orphan Drugs as ZW25 and ZW33; approves FDA

Release Date: 17 October 2016

Zymeworks, a pharmaceutical company, announces that Food and Drug Association (FDA) has granted orphan drug designation to ZW25 and ZW33 for effective treatment of ovarian cancer.

 

Read More

---

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |